PRMT5 and familial pancreatic carcinoma: In conclusion, this study demonstrates that the combination treatment of T1-44, a PRMT5 inhibitor, and Vactosertib, a TGF-β signaling inhibitor, showed impressive synergistic results in improving survival, inhibiting cell invasion and EMT, and stimulating the apoptosis pathway in pancreatic cancer.